Background & Aims
In 2020, the worldwide incidence of cancer was 19.3 million cases and is expected to increase by 47% in the next 20 years.Cancer pain associated with tumors or treatment negatively impacts patients’ quality of life. Cancer pain can occur during all disease periods, being more debilitating when bone metastases occur. Notably, anticancer therapy-induced pain compromises antineoplastic treatment. Thus, analgesics have a significant impact on the well-being of patients with cancer, but an essential and less-studied issue is their effect on disease progression. In addition to the conventional adverse effects, it is valid and prudent to consider evaluating pro-or antitumor activity for new analgesic candidates against pain caused by cancer and its therapy.Kinins and their B1 and B2 receptors are involved in different pain types, including those induced by tumors and anticancer therapy.Moreover, kinins stimulate the proliferation of various tumors while having controversial effect on others.
Methods
This is a review study on the role of kinins in the proliferation of different tumors, analyzing whether it is worth investigating their role in the pain caused by these tumors and their therapy.
Results
Kinins contribute to breast cancer proliferation and pain induced by breast tumor and their therapy, besides other adverse effects of anticancer therapy (nephrotoxicity, cardiotoxicity).Thus, advancing studies on kinins’role in breast cancer proliferation and pain caused by it and its therapy is essential.Kinins are a growth factor for lung and prostate tumors, which frequently metastasize to bones and cause severe pain.Thus, it is valid to investigate the kinins’role in pain caused by these tumors and their therapy.Given the controversial pro-and antitumor studies of kinins in melanoma, it is necessary to clarify this question before advancing the kinins‘role in the pain caused by melanoma and its therapy.Also, it is essential to clarify the kinins‘role, especially the B1 receptor, in the pain and proliferation of primary bone cancer.Other therapies (surgy, radiation, bortezomib, thalidomide) and tumors (gastric, renal, bladder) cause pain whose involvement of kinin could be explored.
Conclusions
A significant clinical challenge is longer-term pain management in cancer patients and survivors, where chronic pain from cancer, its treatment and unrelated causes may overlap. Thus, a therapy capable of treating different cancer pain modalities is essential. Kinin B1 and B2 receptors could be promising pharmacological targets to treat the pain caused by the tumor and its therapy while still reducing tumor proliferation. Although the pro-tumor role seems to prevail, it is essential to review in detail the effect of kinins in each specific type of cancer to investigate their involvement in those that cause pain. Furthermore, many therapies are common to different cancers. Thus, the targets to alleviate anticancer treatment-induced pain should be considered, given the type of cancer. This assessment is also valid and prudent for new analgesic candidates against cancer pain and their therapy, especially to rule out a possible protumor activity of this analgesic.
References
Bennett MI, Kaasa S, Barke A, Korwisi B, Rief W, Treede R-D. The IASP classification of chronic pain for ICD-11: chronic cancer-related pain. Pain 2019;160(1):38–44.
Brusco I, Silva CR, Trevisan G, de Campos Velho Gewehr C, Rigo FK, La Rocca Tamiozzo L, Rossato MF, Tonello R, Dalmolin GD, de Almeida Cabrini D, Gomez MV, Ferreira J, Oliveira SM. Potentiation of Paclitaxel-Induced Pain Syndrome in Mice by Angiotensin I Converting Enzyme Inhibition and Involvement of Kinins. Mol Neurobiol 2017;54(10):7824–7837.
Brusco I, Gabriela B, Vidal PT, Pillat MM, Rahisa S, Trevisol BS, Sampaio TB, Ardisson-Araújo DM, de Andrade CM, Oliveira MS, Machado-De-Avila RA, Oliveira SM. Kinin B1 and B2 receptors mediate cancer pain associated with both the tumor and oncology therapy using aromatase inhibitors. Sci Rep 2023;13:4418.
Bujalska M, Tatarkiewicz J, Gumu?ka SW. Effect of Bradykinin Receptor Antagonists on Vincristine- and Streptozotocin-Induced Hyperalgesia in a Rat Model of Chemotherapy-Induced and Diabetic Neuropathy. Pharmacology 2008;81(2):158–163.
Choi JH, Ro JY. The 2020 WHO Classification of Tumors of Bone: An Updated Review. Adv Anat Pathol 2021;28(3):119–138.
Chopra B, Barrick SR, Meyers S, Beckel JM, Zeidel ML, Ford APDW, De Groat WC, Birder LA. Expression and function of bradykinin B1 and B2 receptors in normal and inflamed rat urinary bladder urothelium. J Physiol 2005;562(3):859–871.
da Costa PLN, Sirois P, Tannock IF, Chammas R. The role of kinin receptors in cancer and therapeutic opportunities. Cancer Lett 2014;345(1):27–38.
Doornebal CW, Vrijland K, Hau C-S, Coffelt SB, Ciampricotti M, Jonkers J, de Visser KE, Hollmann MW. Morphine does not facilitate breast cancer progression in two preclinical mouse models for human invasive lobular and HER2+ breast cancer. Pain 2015;156(8):1424–1432.
Dubuc C, Savard M, Bovenzi V, Lessard A, Côté J, Neugebauer W, Geha S, Chemtob S, Gobeil F. Antitumor activity of cell?penetrant kinin B1 receptor antagonists in human triple?negative breast cancer cells. J Cell Physiol 2019;234(3):2851–2865.
Figueroa CD, Ehrenfeld P, Bhoola KD. Kinin receptors as targets for cancer therapy. Expert Opin Ther Targets 2012;16299–312.
Fujita M, Andoh T, Ohashi K, Akira A, Saiki I, Kuraishi Y. Roles of kinin B 1 and B 2 receptors in skin cancer pain produced by orthotopic melanoma inoculation in mice. Eur J Pain 2010;14(6):588–594.
Glare PA, Davies PS, Finlay E, Gulati A, Lemanne D, Moryl N, Oeffinger KC, Paice JA, Stubblefield MD, Syrjala KL. Pain in cancer survivors. J Clin Oncol. 2014 Jun 1;32(16):1739-47.
Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci 2006;7(10):797–809.
Maria AG, Dillemburg-Pilla P, Durand MT, Floriano EM, Manfiolli AO, Ramos SG, Pesquero JB, Nahmias C, Costa-Neto CM. Activation of the Kinin B1 Receptor by Its Agonist Reduces Melanoma Metastasis by Playing a Dual Effect on Tumor Cells and Host Immune Response. Front Pharmacol. 2019 Sep 25;10:1106.
Morissette G, Houle S, Gera L, Stewart JM, Marceau F. Antagonist, partial agonist and antiproliferative actions of B-9870 (CU201) as a function of the expression and density of the bradykinin B 1 and B 2 receptors. Br J Pharmacol 2007;150(3):369–379.
Park SB, Goldstein D, Krishnan A V., Lin CS-Y, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC. Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA Cancer J Clin 2013;63(6):419–437.
Rassias G, Leonardi S, Rigopoulou D, Vachlioti E, Afratis K, Piperigkou Z, Koutsakis C, Karamanos NK, Gavras H, Papaioannou D. Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved? Eur J Med Chem 2021;210112948.
Sevcik MA, Ghilardi JR, Halvorson KG, Lindsay TH, Kubota K, Mantyh PW. Analgesic efficacy of bradykinin B1 antagonists in a murine bone cancer pain model. J Pain. 2005 Nov;6(11):771-5.
Slosky LM, BassiriRad NM, Symons AM, Thompson M, Doyle T, Forte BL, Staatz WD, Bui L, Neumann WL, Mantyh PW, Salvemini D, Largent-Milnes TM, Vanderah TW. The cystine/glutamate antiporter system xc ? drives breast tumor cell glutamate release and cancer-induced bone pain. Pain 2016;157(11):2605–2616.
Sisignano M, Baron R, Scholich K, Geisslinger G. Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain. Nat Rev Neurol 10:694–707, 2014.
Srivastava S, Sharma K, Kumar N, Roy P. Bradykinin Regulates Osteoblast Differentiation by Akt/ERK/NF?B Signaling Axis. J Cell Physiol 2014;229(12):2088–2105.
Stewart JM, Chan DC, Simkeviciene V, Bunn PA, Helfrich B, York EJ, Taraseviciene-Stewart L, Bironaite D, Gera L. Bradykinin antagonists as new drugs for prostate cancer. Int Immunopharmacol 2002;2(13–14):1781–1786.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71(3):209–249.
Ulrich H, Ratajczak MZ, Schneider G, Adinolfi E, Orioli E, Ferrazoli EG, Glaser T, Corrêa-Velloso J, Martins PCM, Coutinho F, Santos APJ, Pillat MM, Sack U, Lameu C. Kinin and Purine Signaling Contributes to Neuroblastoma Metastasis. Front Pharmacol 2018;9500.
Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006;116(1):271–284.
Wright JK, Botha JH, Naidoo S. Influence of the Kallikrein-Kinin System on Prostate and Breast Tumour Angiogenesis. Tumor Biol 2008;29(2):130–136.
Presenting Author
Indiara Brusco
Poster Authors
Topics
- Specific Pain Conditions/Pain in Specific Populations: Cancer Pain & Palliative Care